Inflammatory markers in heart failure: Hype or hope?

Journal of Cardiovascular Medicine

Volumn 14, Issue 5, 2013, Pages 342-350

  Cialdella, Pio ^a   Pedicino, Daniela ^a   Gustapane, Massimo ^a   Santangeli, Pasquale ^a   Narducci, Maria Lucia ^a   Pelargonio, Gemma ^a   Basile, Eloisa ^a   Giglio, Ada Francesca ^a   Pazzano, Vincenzo ^a   Vitulano, Nicola ^a   Bellocci, Fulvio ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

C reactive protein; Cytokines; Heart failure; Inflammatory biomarkers; Tumor necrosis factor

Indexed keywords

ALDOSTERONE RECEPTOR; AMLODIPINE; ANTIINFLAMMATORY AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CANDESARTAN; CYTOKINE; CYTOKINE RECEPTOR ANTAGONIST; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ETANERCEPT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1; INTERLEUKIN 6; METOPROLOL; NITRIC OXIDE; SPHINGOSINE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE CORONARY SYNDROME; ANTIINFLAMMATORY ACTIVITY; CALCIUM CELL LEVEL; CARDIOMYOPATHY; CHEMOTAXIS; CONGESTIVE CARDIOMYOPATHY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; EXTRACELLULAR MATRIX; FUNCTIONAL STATUS; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; HEART MUSCLE INJURY; HEART MUSCLE PERFUSION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE REMODELING; HUMAN; INFLAMMATION; INOTROPISM; ISCHEMIC CARDIOMYOPATHY; ISCHEMIC HEART DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHYSICAL ACTIVITY; PRIMARY PREVENTION; PROGNOSIS; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SEPTIC SHOCK; SIGNAL TRANSDUCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SUDDEN CARDIAC DEATH; THROMBOCYTE ACTIVATION;

ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; CARDIOVASCULAR AGENTS; HEART FAILURE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS;

EID: 84879506617     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0b013e328349afb6     Document Type: Review

References (74)

1. McMurray JJ, Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart 2000; 83:596-602. (Pubitemid 30316742)
2. Elster SK, Braunwald E, Wood HF. A study of C-reactive protein in the serum of patients with congestive heart failure. Am Heart J 1956; 51:533-541.
3. Vasan RS, Sullivan LM, Roubenoff R, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 2003; 107:1486-1491. (Pubitemid 36378485)
4. Krishnamurthy P, Rajasingh J, Lambers E, Qin G, Losordo DW, Kishore R. IL-10 inhibits inflammation and attenuates left ventricular remodeling after myocardial infarction via activation of STAT3 and suppression of HuR. Circ Res 2009; 104:e9-e18.
5. Oppenheim JJ, Matsushima K, Yoshimura T, Leonard EJ, Neta R. Relationship between interleukin 1 (IL1), tumor necrosis factor (TNF) and neutrophil attracting peptide (NAP-1). Agents Actions 1989; 26:134-140. (Pubitemid 19034632)
6. Tracey KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234:470-474. (Pubitemid 17181429)
7. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992; 257:387-389.
8. Natanson C, Eichenholz PW, Danner RL, et al. Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J Exp Med 1989; 169:823-832. (Pubitemid 19085823)
9. Pagani FD, Baker LS, Hsi C, Knox M, Fink MP, Visner MS. Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factoralpha in conscious dogs. J Clin Invest 1992; 90:389-398.
10. Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL. Cellular basis for the negative inotropic effects of tumor necrosis factoralpha in the adult mammalian heart. J Clin Invest 1993; 92:2303-2312. (Pubitemid 23333536)
11. Heinzel FR, Gres P, Boengler K, et al. Inducible nitric oxide synthase expression and cardiomyocyte dysfunction during sustained moderate ischemia in pigs. Circ Res 2008; 103:1120-1127.
12. Thielmann M, Dörge H, Martin C, et al. Myocardial dysfunction with coronary microembolization: signal transduction through a sequence of nitric oxide, tumor necrosis factor-alpha, and sphingosine. Circ Res 2002; 90:807-813. (Pubitemid 34633897)
13. Canton M, Skyschally A, Menabò R, et al. Oxidative modification of tropomyosin and myocardial dysfunction following coronary microembolization. Eur Heart J 2006; 27:875-881.
14. Heusch G, Schulz R. A radical view on the contractile machinery in human heart failure. J Am Coll Cardiol 2011; 57:310-312.
15. Hosenpud JD, Campbell SM, Mendelson DJ. Interleukin-1-induced myocardial depression in an isolated beating heart preparation. J Heart Transplant 1989; 8:460-464. (Pubitemid 20044100)
16. Kinugawa K, Takahashi T, KohmotoO, et al. Nitric oxide-mediated effects of interleukin-6 on [Ca2+]i and cell contraction in cultured chick ventricular myocytes. Circ Res 1994; 75:285-295.
17. Schulz R, Heusch G. C-reactive protein: just a biomarker of inflammation or a pathophysiological player in myocardial function and morphology? Hypertension 2011; 57:151-153.
18. Zimmermann O, Bienek-Ziolkowski M, Wolf B, et al. Myocardial inflammation and nonischaemic heart failure: is there a role for C-reactive protein? Basic Res Cardiol 2009; 104:591-599.
19. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 2000; 101:2981- 2988. (Pubitemid 30415891)
20. Yokoyama T, Nakano M, Bednarczyk JL, McIntyre BW, Entman M, Mann DL. Tumor necrosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes. Circulation 1997; 95:1247-1252. (Pubitemid 27097837)
21. Comstock KL, Krown KA, Page MT, et al. LPS-induced TNF-alpha release from and apoptosis in rat cardiomyocytes: obligatory role for CD14 in mediating the LPS response. J Mol Cell Cardiol 1998; 30:2761-2775. (Pubitemid 29017515)
22. Deardorff R, Spinale FG. Cytokines and matrix metalloproteinases as potential biomarkers in chronic heart failure. Biomark Med 2009; 3:513- 523.
23. Heusch G, Kleinbongard P, Böse D, et al. Coronary microembolization: from bedside to bench and back to bedside. Circulation 2009; 120:1822- 1836.
24. VolzHC, Seidel C, Laohachewin D, et al. HMGB1: the missing link between diabetes mellitus and heart failure. Basic Res Cardiol 2010; 105:805- 820.
25. Voigt A, Bartel K, Egerer K, et al. Humoral antiproteasomal autoimmunity in dilated cardiomyopathy. Basic Res Cardiol 2010; 105:9-18.
26. Huang CH, Vallejo JG, Kollias G, Mann DL. Role of the innate immune system in acute viral myocarditis. Basic Res Cardiol 2009; 104:228-237.
27. Sandek A, Bauditz J, Swidsinski A, et al. Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol 2007; 50:1561- 1569. (Pubitemid 47532323)
28. Aker S, Belosjorow S, Konietzka I, et al. Serum but not myocardial TNFalpha concentration is increased in pacing-induced heart failure in rabbits. Am J Physiol Regul Integr Comp Physiol 2003; 285:R463-R469. (Pubitemid 36898915)
29. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323:236-241. (Pubitemid 20225044)
30. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996; 27:1201-1206. (Pubitemid 26117714)
31. Sabatine MS, Morrow DA, Jablonski KA, et al. Prognostic significance of the Centers for Disease Control/American Heart Association highsensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation 2007; 115:1528-1536. (Pubitemid 46648637)
32. Arroyo-Espliguero R, Avanzas P, Quiles J, Kaski JC. C-reactive protein predicts functional status and correlates with left ventricular ejection fraction in patients with chronic stable angina. Atherosclerosis 2009; 205:319-324.
33. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001; 103:2055-2059. (Pubitemid 32373007)
34. Koh KK. Effects of estrogen on the vascular wall: vasomotor function and inflammation. Cardiovasc Res 2002; 55:714-726.
35. Januzzi JL Jr, Camargo CA, Anwaruddin S, et al. The N-terminal Pro- BNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Am J Cardiol 2005; 95:948-954. (Pubitemid 40487743)
36. Maisel AS, McCord J, Nowak RM, et al. Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol 2003; 41:2010-2017. (Pubitemid 36677124)
37. Maisel A, Hollander JE, Guss D, et al. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol 2004; 44:1328-1333. (Pubitemid 39208893)
38. Chirinos JA, Zambrano JP, Chakko S, et al. Usefulness of C-Reactive Protein as an independent predictor of death in patients with ischemic cardiomyopathy. Am J Cardiol 2005; 95:88-90. (Pubitemid 40051115)
39. Windram J, Loh PH, Rigby AS, Hanning I, Clark AL, Cleland JGF. Relationship of high-sensitivity C-reactive protein to prognosis and other prognostic markers in outpatients with heart failure. Am Heart J 2007; 153:1048-1055. (Pubitemid 46809860)
40. Michelucci A, Ricciardi G, Sofi F, et al. Relation of inflammatory status to major adverse cardiac events and reverse remodeling in patients undergoing cardiac resynchronization therapy. J Card Fail 2007; 13:207- 210. (Pubitemid 46590037)
41. Rauchhaus M, Doehner W, Francis DP, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000; 102:3060-3067.
42. Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003; 108:3006-3010. (Pubitemid 37553570)
43. Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104:2886-2891. (Pubitemid 33139098)
44. Shehab AM, MacFadyen RJ, McLaren M, Tavendale R, Belch JJ, Struthers AD. Sudden unexpected death in heart failure may be preceded by short term, intraindividual increases in inflammation and in autonomic dysfunction: a pilot study. Heart 2004; 90:1263-1268.
45. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006; 48:e247-e346.
46. Biasucci LM, Giubilato G, Biondi-Zoccai G, et al. C reactive protein is associated with malignant ventricular arrhythmias in patients with ischaemia with implantable cardioverter-defibrillator. Heart 2006; 92:1147-1148. (Pubitemid 44125242)
47. Bellocci F, Biasucci LM, Gensini GF, et al. Prognostic role of postinfarction C-reactive protein in patients undergoing implantation of cardioverterdefibrillators: design of the C-reactive protein Assessment after Myocardial Infarction to GUide Implantation of DEfibrillator (CAMI GUIDE) study. J Cardiovasc Med (Hagerstown) 2007; 8:293-299. (Pubitemid 46586670)
48. Hernández-Presa M, Bustos C, Ortego M, et al. Angiotensin- converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 1997; 95:1532-1541. (Pubitemid 27142812)
49. Prabhu SD, Chandrasekar B, Murray DR, Freeman GL. Beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation 2000; 101:2103- 2109. (Pubitemid 30233176)
50. Kohno T, Anzai T, Naito K, et al. Angiotensin-receptor blockade reduces border zone myocardial monocyte chemoattractant protein-1 expression and macrophage infiltration in postinfarction ventricular remodeling. Circ J 2008; 72:1685-1692.
51. Schieffer B, Schieffer E, Hilfiker-Kleiner D, et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 2000; 101:1372-1378. (Pubitemid 30169857)
52. Gage JR, Fonarow G, Hamilton M, Widawski M, Martínez-Maza O, Vredevoe DL. Beta blocker and angiotensin-converting enzyme inhibitor therapy is associated with decreased Th1/Th2 cytokine ratios and inflammatory cytokine production in patients with chronic heart failure. Neuroimmunomodulation 2004; 11:173-180. (Pubitemid 38453113)
53. Gullestad L, Aukrust P, Ueland T, et al. Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol 1999; 34:2061-2067. (Pubitemid 30002665)
54. Mohler ER III, Sorensen LC, Ghali JK, et al. Role of cytokines in the mechanism of action of amlodipine: the PRAISE Heart Failure Trial. Prospective Randomized Amlodipine Survival Evaluation. J Am Coll Cardiol 1997; 30:35-41. (Pubitemid 27357124)
55. Maeda K, Tsutamoto T, Wada A, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000; 36:1587-1593.
56. Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and nonischemic heart failure. J Am Coll Cardiol 2004; 43:642-648. (Pubitemid 38229538)
57. Node K, Fujita M, Kitakaze M, Hori M, Liao JK. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003; 108:839-843. (Pubitemid 37022126)
58. Kjekshus J, Dunselman P, Blideskog M, et al. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail 2005; 7:1059-1069. (Pubitemid 41443603)
59. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357:2248-2261. (Pubitemid 350190755)
60. McMurray JJ, Kjekshus J, Gullestad L, et al. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation 2009; 120:2188-2196.
61. van der Harst P, Slart RH, Tio RA, et al. Effects of rosuvastatin on coronary flow reserve and metabolic mismatch in patients with heart failure (from the CORONA Study). Am J Cardiol 2010; 105:517-521.
62. Andreou I, Tousoulis D, Miliou A, et al. Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: a randomized placebo-controlled study. Atherosclerosis 2010; 210:194-198.
63. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT, Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107:3133- 3140. (Pubitemid 36793081)
64. Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004; 109:1594-1602. (Pubitemid 38451714)
65. Kleinbongard P, Heusch G, Schulz R. TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure. Pharmacol Ther 2010; 127:295-314.
66. Skyschally A, Gres P, Hoffmann S, et al. Bidirectional role of tumor necrosis factor-alpha in coronary microembolization: progressive contractile dysfunction versus delayed protection against infarction. Circ Res 2007; 100:140-146. (Pubitemid 46066782)
67. Maisel AS, Bhalla V, Braunwald E. Cardiac biomarkers: a contemporary status report. Nat Clin Pract Cardiovasc Med 2006; 3:24-34. (Pubitemid 43078210)
68. Sinning C, Schnabel R, Peacock WF, Blankenberg S. Up-and-coming markers: myeloperoxidase, a novel biomarker test for heart failure and acute coronary syndrome application? Congest Heart Fail 2008; 14:46-48.
69. Yan RT, Fernandes V, Yan AT, et al. Fibrinogen and left ventricular myocardial systolic function: The Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J 2010; 160:479-486.
70. Ikonomidis I, Lekakis JP, Nikolaou M, et al. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation 2008; 117:2662-2669.
71. Abbate A, Kontos MC, Grizzard JD, et al. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am J Cardiol 2010; 105:1371-1377.
72. Serra AJ, Santos MH, Bocalini DS, et al. Exercise training inhibits inflammatory cytokines and more than prevents myocardial dysfunction in rats with sustained beta-adrenergic hyperactivity. J Physiol 2010; 588:2431-2442.
73. Gielen S, Adams V, Möbius-Winkler S, et al. Anti-inflammatory effects of exercise training in the skeletal muscle of patients with chronic heart failure. J Am Coll Cardiol 2003; 42:861-868. (Pubitemid 37059745)
74. Adamopoulos S, Parissis J, Karatzas D, et al. Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fas ligand system in patients with chronic heart failure. J Am Coll Cardiol 2002; 39:653-663. (Pubitemid 34158162)